Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
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
V14E6JL6ErhA7kLW
